<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="369754">
  <stage>Registered</stage>
  <submitdate>18/12/2015</submitdate>
  <approvaldate>12/01/2016</approvaldate>
  <actrnumber>ACTRN12616000009415</actrnumber>
  <trial_identification>
    <studytitle>Open label trial of intramuscular pentosan polysulfate on acute traumatic knee injury </studytitle>
    <scientifictitle>A pilot study investigating the short-term outcome of intramuscular administration of pentosan polysulfate sodium for the treatment of bone marrow lesions of the knee</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>PARA_001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Bone marrow oedema lesion associated with acute traumatic knee injury</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Injuries and Accidents</conditioncode1>
      <conditioncode2>Other injuries and accidents</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Single arm study -Twice weekly injections of pentosan polysulfate (PPS) for 3 weeks administered intra muscularly at a dose of 2 mg/kg.

PPS will be administered at the study site by clinical staff.
No specific strategies to monitor adherence are required.</interventions>
    <comparator>No Control group

Changes from baseline</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Primary study objectives are to evaluate the safety and tolerability.
Specific assessments to evaluate safety and tolerability include the frequency and type of AEs, the use of concomitant medication for management of AEs, clinical laboratory testing (haematology, clinical chemistry, liver function tests, coagulation, urinalysis), physical examination and vital signs.

Particularly attention will be paid to the following types of AE:
-Injection site reactions
-Alopecia
-Abdominal pain, diarrhoea, nausea, dyspepsia, bleeding
-Headache
-Skin rashes</outcome>
      <timepoint>Day: 0, 4, 7, 11, 14, 18, 28, 42, 56

Day 0=first dose of study drug</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in bone marrow lesions assessed by MRI</outcome>
      <timepoint>8 weeks post first injection</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>functional knee joint capacity assessed by Lysholm Knee score and Tegner Activity score</outcome>
      <timepoint>Day: 0, 4, 7, 11, 14, 18, 28, 42, 56

Day 0=first dose of study drug</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Biomarkers- serum biomarkers of bone and collagen activity and inflammation</outcome>
      <timepoint>Day: 0, 7, 14, 28, 42, 56

Day 0=first dose of study drug</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pain assessed by Numeric Rating Scale NRS-11</outcome>
      <timepoint>Day: 0, 4, 7, 11, 14, 18, 28, 42, 56

Day 0=first dose of study drug</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Subjects who have experienced an acute anterior cruciate ligament (ACL) injury a minimum of 1 week and maximum of 14 weeks prior to Day 0, and have been managed conservatively with physical therapy and medications 
Subjects with bone marrow lesions of the femur or tibia on at least 2 consecutive sagittal or coronal MRI slices as confirmed by an independent reader.
OR 
subjects who have experienced an acute anterior cruciate ligament (ACL) injury a minimum of 2 weeks maximum of 14 weeks prior to Day 0 and have been treated with surgical intervention to repair the acute injury within a minimum of 2 weeks and maximum of 14 weeks prior to Day 0.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>50</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Subjects who have been treated with surgical intervention for the ACL injury in the affected knee
2. Subjects in whom surgery for the ACL injury in the affected knee is planned during the study period
3. Osteonecrosis, osseous infection/inflammation or visible cartilage damage of the affected joint
4. Systemic arthritis or osteoarthritis (OA) in multiple other joints</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Not Applicable</concealment>
    <sequence>Not Applicable</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods>Descriptive statistics no formal hypothesis testing</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>25/01/2016</anticipatedstartdate>
    <actualstartdate>20/02/2016</actualstartdate>
    <anticipatedenddate>31/07/2017</anticipatedenddate>
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA,VIC</recruitmentstate>
    <hospital>Sportsmed SA Hospital - Stepney</hospital>
    <postcode>5052 - Belair</postcode>
    <postcode>3128 - Box Hill Central</postcode>
    <postcode>5069 - Stepney</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Paradigm BioPharmaceuticals Ltd</primarysponsorname>
    <primarysponsoraddress>Level 2, 
517 Flinders Lane, 
Melb, VIC, 3000, AUSTRALIA</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Paradigm BioPharmaceuticals Ltd</fundingname>
      <fundingaddress>Level 2, 
517 Flinders Lane, 
Melb, VIC, 3000, AUSTRALIA</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The main aim of this study is to see whether pentosan polysulfate sodium (PPS) is safe and effective in treating Bone Marrow Oedema Lesion (BML) associated with acute knee injury and thereby relieving the pain caused by BML. Every person who participates in this study will receive a course of PPS injections.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>BELLBERRY HUMAN RESEARCH ETHICS COMMITTEE</ethicname>
      <ethicaddress>129 Glen Osmond Rd
Eastwood SA 5063

Phone: 08 8361 3222
Fax: 08 8361 3322</ethicaddress>
      <ethicapprovaldate>20/11/2015</ethicapprovaldate>
      <hrec>2015-10-686</hrec>
      <ethicsubmitdate>14/10/2015</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Jegan Krishnan</name>
      <address>Southern Adelaide Health Institute Inc. 
13 Laffers Road,
Belair SA 5052</address>
      <phone>618 82044279</phone>
      <fax />
      <email>Jegan@Krishnan.com.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Paul Rennie</name>
      <address>Paradigm BioPharmaceuticals Ltd
Level 2, 
517 Flinders Lane, 
Melb, VIC, 3000, 
AUSTRALIA</address>
      <phone>+61 437 778 300</phone>
      <fax />
      <email>prennie@paradigmbiopharma.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Ravi Krishnan</name>
      <address>Paradigm BioPharmaceuticals Ltd
Level 2, 
517 Flinders Lane, 
Melb, VIC, 3000, 
AUSTRALIA</address>
      <phone>+61412095125</phone>
      <fax />
      <email>rkrishnan@paradigmbiopharma.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Ravi Krishnan</name>
      <address>Paradigm BioPharmaceuticals Ltd
Level 2, 
517 Flinders Lane, 
Melb, VIC, 3000, 
AUSTRALIA</address>
      <phone>+61412095125</phone>
      <fax />
      <email>rkrishnan@paradigmbiopharma.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>